Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) saw unusually-high trading volume on Monday . Approximately 1,456,959 shares were traded during trading, a decline of 1% from the previous session’s volume of 1,472,419 shares.The stock last traded at $99.46 and had previously closed at $96.86.

BMRN has been the topic of several research analyst reports. Vetr raised shares of BioMarin Pharmaceutical from a “buy” rating to a “strong-buy” rating and set a $111.64 price target on the stock in a research note on Wednesday, August 24th. Credit Suisse Group AG reissued a “buy” rating and set a $114.00 price target (up from $103.00) on shares of BioMarin Pharmaceutical in a research note on Monday, June 13th. Wedbush reissued a “neutral” rating and set a $108.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, July 28th. Jefferies Group reissued a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Wednesday, August 17th. Finally, Zacks Investment Research raised shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and set a $111.00 price target on the stock in a research note on Tuesday, August 9th. Three analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $120.61.

The company’s market cap is $16.04 billion. The company has a 50 day moving average price of $95.76 and a 200 day moving average price of $88.19.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($2.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $2.09. BioMarin Pharmaceutical had a negative net margin of 54.53% and a negative return on equity of 11.99%. The business earned $300.10 million during the quarter, compared to analyst estimates of $278.75 million. During the same quarter last year, the company posted ($0.51) earnings per share. The company’s revenue was up 20.0% compared to the same quarter last year. Equities research analysts predict that BioMarin Pharmaceutical Inc. will post ($3.95) EPS for the current year.

In other BioMarin Pharmaceutical news, CEO Jean Jacques Bienaime sold 41,666 shares of the company’s stock in a transaction that occurred on Monday, July 18th. The shares were sold at an average price of $92.72, for a total value of $3,863,271.52. Following the completion of the transaction, the chief executive officer now directly owns 420,250 shares in the company, valued at approximately $38,965,580. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP George Eric Davis sold 2,167 shares of the company’s stock in a transaction that occurred on Thursday, July 7th. The shares were sold at an average price of $90.00, for a total transaction of $195,030.00. Following the completion of the transaction, the executive vice president now owns 72,836 shares of the company’s stock, valued at $6,555,240. The disclosure for this sale can be found here. 2.50% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the stock. Pacer Advisors Inc. raised its stake in BioMarin Pharmaceutical by 1.2% in the second quarter. Pacer Advisors Inc. now owns 4,339 shares of the company’s stock worth $338,000 after buying an additional 52 shares in the last quarter. Hartford Investment Management Co. raised its stake in BioMarin Pharmaceutical by 2.5% in the second quarter. Hartford Investment Management Co. now owns 2,906 shares of the company’s stock worth $226,000 after buying an additional 70 shares in the last quarter. Essex Investment Management Co. LLC raised its stake in BioMarin Pharmaceutical by 0.6% in the second quarter. Essex Investment Management Co. LLC now owns 15,411 shares of the company’s stock worth $1,199,000 after buying an additional 90 shares in the last quarter. Mn Services Vermogensbeheer B.V. raised its stake in BioMarin Pharmaceutical by 2.3% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 4,082 shares of the company’s stock worth $286,000 after buying an additional 90 shares in the last quarter. Finally, Glenmede Trust Co. NA raised its stake in BioMarin Pharmaceutical by 0.7% in the second quarter. Glenmede Trust Co. NA now owns 16,639 shares of the company’s stock worth $1,293,000 after buying an additional 114 shares in the last quarter. Hedge funds and other institutional investors own 93.11% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

5 Day Chart for NASDAQ:BMRN

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.